Creating new drugs is notoriously expensive and time - consuming and, with tropical diseases, the financial incentive isn't there
for big drug companies who...
But as its patent expires on November 30 and its first generic competitor takes the stage, Lipitor is also a painful reminder of the challenge that such «patent cliffs» pose
for the big drug companies, including Lipitor's developer Pfizer, based in New York.
It is also restricted almost entirely to Africa, which, unfortunately for its victims, makes it a less attractive target
for big drug companies than a host of non-fatal diseases (think erectile dysfunction) that are more common in rich countries.
Not exact matches
STAT reached out to the 15
biggest drug companies about the immigration ban; only Johnson & Johnson, Merck, and Novartis responded with statements — and they simply expressed support
for affected employees, without taking a stance on Trump's action.
Add one more name to the new slew of pharma
companies trying to counteract the public backlash to
big drug price increases: France's Sanofi, a $ 126 billion firm known
for its flagship diabetes and vaccines units.
This is quite a
big deal as Valeant bought Sprout Pharmaceuticals, the
company behind the
drug for a whopping $ 1 billion just over two years ago.
While Tesaro is remaining publicly coy
for now, a buyout has always been in the cards as
big pharma
companies continue to snap up biotechs that have already done
drug development legwork
for them.
Another value play
for 2017 could be Novartis, a Swiss diversified
drug company and the world's
biggest prescription drugmaker.
Such
big winners stopped showing up a few years ago, leaving the large
drug companies watching the calendar
for the day when earnings would be hurt by the loss of key patent protections.
In May generic
drug company Actavis Inc. agreed to buy Warner Chilcott PLC
for $ 8.5 billion in stock, creating the third -
biggest specialty pharmaceutical
company in the U.S. market.
As
big pharmaceutical
companies find that the patents
for some of their blockbuster
drugs are expiring, they are desperately reaching out to replenish their
drug pipelines.
They often license promising
drugs to
bigger pharmaceutical
companies, which help pay
for development and become responsible
for making sales.
As
for stem cell research, I don't think you understand the reach of these
big drug companies.
Kay Abadee, VP of marketing at Axiom, noted that
bigger companies were looking particularly
for pea proteins with Generally Recognized As Safe (GRAS) certification from the U.S. Food and
Drug Administration (FDA).
«
For example; McCain and Palin claimed the donars are largely unknown for Obama, while they have taken campaign money for years from big donors such as Freddie and Fannie, AIG, Oil companies, Drug companies etc.,&raq
For example; McCain and Palin claimed the donars are largely unknown
for Obama, while they have taken campaign money for years from big donors such as Freddie and Fannie, AIG, Oil companies, Drug companies etc.,&raq
for Obama, while they have taken campaign money
for years from big donors such as Freddie and Fannie, AIG, Oil companies, Drug companies etc.,&raq
for years from
big donors such as Freddie and Fannie, AIG, Oil
companies,
Drug companies etc.,»
David Kessler, the former commissioner of the Food and
Drug Administration, is calling
for a
big government - funded research project to help fill in the gaps in genetic pathways in people, which are turning out to be far more complex than expected
for illnesses such as heart disease and which may be beyond the ability of private
companies and smaller labs to figure out and pay
for.
As well, pharmaceutical
companies are looking
for new ways to address their two - pronged pipeline problem: many
big - name blockbuster
drugs will soon lose their patents and, perhaps more important, there is a dearth of new blockbusters headed to the market.
The most important change occurring in the industry is a shift away from the traditional «
big pharma» model
for drug development, in which research and development are concentrated inside such
companies as Pfizer, Merck, and AstraZeneca.
Like other
big pharma
companies, Pfizer is partnering with academic institutions to share the risk of
drug development and take advantage of academic scientists» broad base of knowledge, says Boston - based Anthony Coyle, vice president of the Centers
for Therapeutic Innovation (CTI) at Pfizer.
He will assemble a group of people to voluntarily try an existing
drug for a new application before a pharmaceutical
company embarks on a
bigger, more costly human trial.
Companies like 23andMe that offer to reveal your genetic secrets from a spit test can also sell your data to
drug developers
for big sums
The
biggest UK employers in industry are Smith & Nephew, a research
company focused on wound care, and
drug company Pfizer, whose research includes developing stem cell therapies
for Crohn's disease.
The crucial
drugs are unlikely to be
big moneymakers
for companies that develop them, so governments and health agencies need to cooperate to boost the chances that they will be developed in time, notes Marie - Paule Kieny, WHO's assistant director - general
for health systems and innovation.
A few
drug companies have kicked the tires on stem cells over the years, but waiting
for them to undo the current model is akin to banking on
Big Oil to rethink energy.
At the same time that Purdue and other
big pharma
companies were hosting symposia, they doubled their sales force and gave doctors 30 - day free coupons so they could let patients try these
drugs for pain that previously wasn't managed using opiates.
Steven Sinatra, MD remarked in his writings that
drug companies Merck and Pfizer have transformed the medical profession into one
big vending machine
for statin
drugs.
Nina and I are friends as well, even though I say her name wrong, who has also written some books about fat, but there's this national conversation where you have the old school low - fats, mostly paid
for by
big grain sort of research out there, and you're refuting some of that using very strong academics, randomized controlled trials, and the things that everyone wants, but no one has paid
for except
for maybe
big drug companies and things like that.
In the UK we are fighting to save our NHS from privatisation and more influence from
big business and
drug companies, at the same time we also need to campaign
for public medicine to become smarter in the way that it deals with diabesity.
Long - term studies of animal immunity would require a substantial outlay of money — the kind of money that only the
drug companies have, and
Big Pharma is much more interested in selling more vaccines than challenging the need
for them.
Similarly, biomedical and pharmaceutical research is bedazzled by molecular genetics, has sequenced the genome of one or two humans and a handful of other species and invested trillions on very rigidly reductionistic bottom - up research into medicines and diseases — with the result of empty
drug pipelines
for the
big pharma
companies in spite of all this investment.
The
drug injury and medical malpractice lawyers at Altman & Altman, LLP believe that the
big pharmaceutical
companies should be held accountable
for their negligence, especially when it comes at the expense of thousands of lives.
When
big drug companies put profits above the safety and wellbeing of the general public, we believe they should be held accountable
for their actions.
Just recently one
big pharmaceutical
company was fined 1.2 billion dollars
for failing to disclose possible serious side effects of one of their FDA - approved
drugs.
Summary of Qualifications * President and owner Coastal
Drug Institutional Pharmacy in Maryland * 10 yrs as Pharmacist in Charge
for Long Term Care Pharmacy * Senior Management Consultant
for Big 5 consulting firm * Six Sigma Black Belt * Associate Director of Project Management
for biopharmaceutical
company * Director of Clinical Benchmarking
for mid-tier consulting firm * Project Manager
for top 10 pharmaceutical
company *...